What to expect from genomic tumour profiling for breast cancer

The laboratory looks for changes in tumour DNA and may assess markers linked with how cancer cells behave or respond to particular medicines. The sample often comes from a previous biopsy or operation, so another procedure may not be needed. If the available tissue is insufficient, the team will explain whether another sample is appropriate.

The report can identify a finding that supports a targeted treatment discussion, suggests that a medicine may be less suitable, or does not provide a treatment match. It is one part of decision-making alongside the cancer’s location, extent, hormone or protein findings, previous treatment, and your preferences.

Ask which sample will be tested, whether the laboratory needs additional tissue, and how long the report may take. Tell the team about current medicines and previous treatments. Ask whether the result could affect a clinical-trial discussion, and what happens if no actionable finding is reported.

When the report is available, request a plain-language explanation of each relevant finding. Do not start, stop, or change treatment from the report alone. Your oncologist will weigh possible benefit, side effects, interactions, and the practical plan for monitoring.

Contact your breast cancer team urgently for new severe breathlessness, chest pain, sudden weakness, heavy bleeding, or rapidly worsening symptoms. Profiling itself is usually a laboratory process, so these symptoms should be assessed as clinical concerns rather than waiting for the report.

Ask: What question is this profile intended to answer? Is my existing tissue suitable? Which findings could change treatment? What does an uninformative result mean? How will this report fit with my hormone-receptor and protein-marker results? When will we review it?